Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Re
- Company
- Moderna, Inc. (MRNA)
- Indication
- Respiratory Syncytial Virus
Other upcoming events for MRNA
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.